{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-192484","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.216694+00:00","generated_at":"2026-06-13T03:17:29.918720+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TScan Therapeutics CFO Brian Silver resigns; CEO MacBeath appointed interim CFO, Dworak as Principal Accounting Officer","bullets":["Brian Silver resigned as CFO, effective July 21, 2023; CEO Gavin MacBeath named interim Principal Financial Officer.","Leiden Dworak appointed Principal Accounting Officer, effective July 21, 2023; previously VP, Finance since April 2022.","Dworak's base salary increased to $340,000; target bonus raised to 35% from 30%; granted 25,000 stock options at $2.23.","Stock options vest over four years (25% one-year cliff, then monthly). No family relationships or related party transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-192484","json":"https://secwatch.observer/filing/0001193125-23-192484.json","markdown":"https://secwatch.observer/filing/0001193125-23-192484.md","text":"https://secwatch.observer/filing/0001193125-23-192484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523192484/0001193125-23-192484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523192484/d845896d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T03:17:29.918720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f070c019b","claim":"Brian Silver resigned as Chief Financial Officer at TScan Therapeutics, Inc..","evidence_excerpt":"replacing Brian Silver, who had previously announced his resignation as Chief Financial Officer of the Company effective July 21, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523192484/0001193125-23-192484-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a0fb3213dc","claim":"Leiden Dworak was appointed as Principal Accounting Officer at TScan Therapeutics, Inc..","evidence_excerpt":"appointed Leiden Dworak as Principal Accounting Officer of the Company, effective July 21, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523192484/0001193125-23-192484-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"d9ffb9f8aa","claim":"Gavin MacBeath was appointed as interim Principal Financial Officer at TScan Therapeutics, Inc..","evidence_excerpt":"appointed Gavin MacBeath, Ph.D., as the interim Principal Financial Officer of the Company, effective July 21, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523192484/0001193125-23-192484-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Principal Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}